Olanzapine induced neuroleptic malignant syndrome

An 18 year old male diagnosed as a case of bipolar affective disorder (BPAD), developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine (20 mg per day), an atypical antipsychotic drug. NMS is usually seen with typical antipsychotic drugs. The patient was diagnosed as a case...

Descripción completa

Detalles Bibliográficos
Autores principales: Patra, Bichitra Nanda, Khandelwal, Sudhir K., Sood, Mamta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608309/
https://www.ncbi.nlm.nih.gov/pubmed/23543750
http://dx.doi.org/10.4103/0253-7613.106448
_version_ 1782264220241362944
author Patra, Bichitra Nanda
Khandelwal, Sudhir K.
Sood, Mamta
author_facet Patra, Bichitra Nanda
Khandelwal, Sudhir K.
Sood, Mamta
author_sort Patra, Bichitra Nanda
collection PubMed
description An 18 year old male diagnosed as a case of bipolar affective disorder (BPAD), developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine (20 mg per day), an atypical antipsychotic drug. NMS is usually seen with typical antipsychotic drugs. The patient was diagnosed as a case of NMS, offending agent was immediately withdrawn and prompt treatment with bromocriptine and levodopa produced a good recovery. The various features of the case are discussed in view of the potential mortality of the syndrome.
format Online
Article
Text
id pubmed-3608309
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-36083092013-03-29 Olanzapine induced neuroleptic malignant syndrome Patra, Bichitra Nanda Khandelwal, Sudhir K. Sood, Mamta Indian J Pharmacol Case Report An 18 year old male diagnosed as a case of bipolar affective disorder (BPAD), developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine (20 mg per day), an atypical antipsychotic drug. NMS is usually seen with typical antipsychotic drugs. The patient was diagnosed as a case of NMS, offending agent was immediately withdrawn and prompt treatment with bromocriptine and levodopa produced a good recovery. The various features of the case are discussed in view of the potential mortality of the syndrome. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3608309/ /pubmed/23543750 http://dx.doi.org/10.4103/0253-7613.106448 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Patra, Bichitra Nanda
Khandelwal, Sudhir K.
Sood, Mamta
Olanzapine induced neuroleptic malignant syndrome
title Olanzapine induced neuroleptic malignant syndrome
title_full Olanzapine induced neuroleptic malignant syndrome
title_fullStr Olanzapine induced neuroleptic malignant syndrome
title_full_unstemmed Olanzapine induced neuroleptic malignant syndrome
title_short Olanzapine induced neuroleptic malignant syndrome
title_sort olanzapine induced neuroleptic malignant syndrome
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608309/
https://www.ncbi.nlm.nih.gov/pubmed/23543750
http://dx.doi.org/10.4103/0253-7613.106448
work_keys_str_mv AT patrabichitrananda olanzapineinducedneurolepticmalignantsyndrome
AT khandelwalsudhirk olanzapineinducedneurolepticmalignantsyndrome
AT soodmamta olanzapineinducedneurolepticmalignantsyndrome

Ejemplares similares